| HOME | HELP | CONTACT US | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Direct immunoassay of plasma corticotrophin-releasing hormone (CRH) is potentially subject to interference from high levels of CRH-binding protein (CRH-BP) that exist in the human circulation. In this study, we tested the effect of CRH-free, native CRH-BP (6·4 nmol/l) purified from human plasma, CRH-BP diluent alone, normal human plasma (containing 5·8 nmol endogenous CRH-BP/1) and normal sheep plasma (containing no CRH-BP) on the binding of 125I-labelled CRH tracer to five N-terminal and four C-terminal CRH antibodies. All anti-(1–20)CRH N-terminal antibody dilution curves displayed marked inhibition of binding in the presence of purified CRH-BP and human plasma in comparison with the curves with the control diluent or sheep plasma. Almost no inhibition of binding was obtained with any of the C-terminal antibodies (all directed against epitopes within the last six amino acids of CRH) and the four dilution curves were nearly superimposable. Liquid-phase CRH IRMAs were then developed with different combinations of two of each of the N- and C-terminal antibodies, using radiolabelled IgG prepared from purified C-terminal antisera as tracer and raw N-terminal antisera as the link antibodies to the separating system. The addition of dilutions of purified CRH-BP over the range 1·25–20 nmol/l to the IRMA standard curve in assay buffer resulted in a dose-dependent reduction in the signal; with 5 nmol CRH-BP/1, a level commonly found in human plasma, the reduction in binding was 67% and 81% in two different IRMAs at a CRH concentration of 631 pmol/l. With endogenous CRH-BP in human plasma, a dose-dependent inhibition of binding similarly resulted, with the plasma containing the most CRH-BP causing the greatest inhibition. Since plasma CRH-BP levels in humans vary widely, direct plasma IRMA using these type of antibodies will give inaccurate results and initial extraction of the CRH is necessary. Methanol extraction of synthetic or endogenous CRH is shown to be both highly efficient and unaffected by variable amounts of endogenous or exogenous CRH-BP; it is therefore suitable as the first step in plasma CRH measurement by IRMA.
Journal of Endocrinology (1995) 146, 45–53
This article has been cited by other articles:
|
|
 |
|
  I. S. Yim, L. M. Glynn, C. Dunkel Schetter, C. J. Hobel, A. Chicz-DeMet, and C. A. Sandman Risk of Postpartum Depressive Symptoms With Elevated Corticotropin-Releasing Hormone in Human Pregnancy Arch Gen Psychiatry, February 1, 2009; 66(2): 162 - 169. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Latendresse and R. J. Ruiz Bioassay Research Methodology: Measuring CRH in Pregnancy Biol Res Nurs, July 1, 2008; 10(1): 54 - 62. [Abstract] [PDF]
|
|
|
|
|
|
P. Talley, M. Heitkemper, A. Chicz-Demet, and C. A. Sandman Male violence, stress, and neuroendocrine parameters in pregnancy: a pilot study. Biol Res Nurs, January 1, 2006; 7(3): 222 - 233. [Abstract] [PDF]
|
|
|
|
 |
|
 W. Lu, L. Dow, S. Gumusgoz, M. J. Brierley, J. M. Warne, C. R. McCrohan, R. J. Balment, and D. Riccardi Coexpression of Corticotropin-Releasing Hormone and Urotensin I Precursor Genes in the Caudal Neurosecretory System of the Euryhaline Flounder (Platichthys flesus): A Possible Shared Role in Peripheral Regulation Endocrinology, December 1, 2004; 145(12): 5786 - 5797. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Korebrits, M. M. Ramirez, L. Watson, E. Brinkman, A. D. Bocking, and J. R. G. Challis Maternal Corticotropin-Releasing Hormone Is Increased with Impending Preterm Birth J. Clin. Endocrinol. Metab., May 1, 1998; 83(5): 1585 - 1591. [Abstract] [Full Text]
|
|
|
|
|
|
R. J. Woods, C. F. Kemp, J. David, and P. J. Lowry Heterogeneity of the Human Corticotropin-Releasing Factor-Binding Protein J. Clin. Endocrinol. Metab., May 1, 1997; 82(5): 1566 - 1571. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | CONTACT US | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
